Vestor Capital LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 209.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,787 shares of the company’s stock after buying an additional 7,302 shares during the quarter. Vestor Capital LLC’s holdings in Eli Lilly and Company were worth $9,921,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently made changes to their positions in LLY. Maryland Capital Advisors Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $25,000. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $30,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the period. Finally, Dorato Capital Management purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Price Performance
NYSE:LLY opened at $1,155.97 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The stock has a fifty day moving average of $1,151.01 and a 200 day moving average of $1,043.41. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm has a market capitalization of $1.09 trillion, a price-to-earnings ratio of 41.06, a P/E/G ratio of 1.50 and a beta of 0.51.
Eli Lilly and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 24.58%.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on LLY shares. Leerink Partners lifted their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research note on Monday, July 6th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Barclays raised their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.
View Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company News Roundup
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Manufacturing expansion supports future demand. Lilly and Resilience are investing $750 million to expand U.S. production of diabetes and obesity medicines. The project is expected to add at least 400 jobs in West Chester, Ohio, and lift Resilience’s Ohio workforce above 1,400. Lilly says the investment is part of approximately $55 billion committed to U.S. manufacturing, helping address supply constraints and support growth. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
- Positive Sentiment: Retatrutide reaches a late-stage clinical milestone. Lilly completed a Phase 3 trial of retatrutide, its next-generation obesity and diabetes candidate. The completion sets up a potentially important catalyst when results are released, particularly because the drug could expand Lilly’s position in weight management and related cardiovascular markets. Lilly’s Retatrutide Trial Reaches Completion
- Positive Sentiment: Analyst coverage remains broadly favorable, with brokerages assigning a consensus “Moderate Buy” rating. Commentators also point to Lilly’s expanding drug pipeline beyond its current weight-loss products as a longer-term growth driver. Consensus Recommendation of Moderate Buy
- Neutral Sentiment: Lilly’s planned $2.8 billion acquisition of AtaiBeckley would broaden its pipeline into psychedelic-based treatments, but the deal also introduces development and integration risk and is not an immediate earnings catalyst. Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion
- Negative Sentiment: Erste Group Bank reduced its 2026 EPS forecast to $35.34 from $36.33, although the revised estimate remains above the broader consensus of $34.91. The adjustment may be weighing on sentiment while LLY trades at a premium valuation and near its 12-month high. Eli Lilly Analyst Estimate Update
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
